These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 12734320)

  • 1. Re: Trends in use of adjuvant multi-agent chemotherapy and tamoxifen for breast cancer in the United States: 1975-1999.
    Jordan VC; Morrow M
    J Natl Cancer Inst; 2003 May; 95(9):683-4; author reply 684-5. PubMed ID: 12734320
    [No Abstract]   [Full Text] [Related]  

  • 2. Re: Trends in use of adjuvant multi-agent chemotherapy and tamoxifen for breast cancer in the United States: 1975-1999.
    Du XL
    J Natl Cancer Inst; 2003 May; 95(9):683; author reply 684-5. PubMed ID: 12734321
    [No Abstract]   [Full Text] [Related]  

  • 3. Should women receiving tamoxifen be screened for endometrial cancer? An argument for screening.
    Menzin AW; Gal D; Barakat RR
    Cancer Invest; 2000; 18(8):793-7. PubMed ID: 11107449
    [No Abstract]   [Full Text] [Related]  

  • 4. Gynecologic surveillance of women on tamoxifen: first do no harm.
    Runowicz CD
    J Clin Oncol; 2000 Oct; 18(20):3457-8. PubMed ID: 11032584
    [No Abstract]   [Full Text] [Related]  

  • 5. Tamoxifen therapy for breast cancer and endometrial cancer risk.
    Bernstein L; Deapen D; Cerhan JR; Schwartz SM; Liff J; McGann-Maloney E; Perlman JA; Ford L
    J Natl Cancer Inst; 1999 Oct; 91(19):1654-62. PubMed ID: 10511593
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized trial of tamoxifen versus tamoxifen plus aminoglutethimide as adjuvant treatment in postmenopausal breast cancer patients with hormone receptor-positive disease: Austrian breast and colorectal cancer study group trial 6.
    Schmid M; Jakesz R; Samonigg H; Kubista E; Gnant M; Menzel C; Seifert M; Haider K; Taucher S; Mlineritsch B; Steindorfer P; Kwasny W; Stierer M; Tausch C; Fridrik M; Wette V; Steger G; Hausmaninger H
    J Clin Oncol; 2003 Mar; 21(6):984-90. PubMed ID: 12637461
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Endometrial histopathology in 700 patients treated with tamoxifen for breast cancer.
    Deligdisch L; Kalir T; Cohen CJ; de Latour M; Le Bouedec G; Penault-Llorca F
    Gynecol Oncol; 2000 Aug; 78(2):181-6. PubMed ID: 10926800
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Equivalence between ovarian suppression and chemotherapy in the adjuvant treatment of endocrine-responsive breast cancer.
    Di Leo A; Buyse M
    J Clin Oncol; 2002 Apr; 20(7):1954-5. PubMed ID: 11919262
    [No Abstract]   [Full Text] [Related]  

  • 9. Effect of adjuvant tamoxifen on the endometrium in women with breast cancer: a prospective study using office endometrial biopsy.
    Barakat RR; Gilewski TA; Almadrones L; Saigo PE; Venkatraman E; Hudis C; Hoskins WJ
    J Clin Oncol; 2000 Oct; 18(20):3459-63. PubMed ID: 11032585
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Toremifene-induced fatty liver and NASH in breast cancer patients with breast-conservation treatment.
    Hamada N; Ogawa Y; Saibara T; Murata Y; Kariya S; Nishioka A; Terashima M; Inomata T; Yoshida S
    Int J Oncol; 2000 Dec; 17(6):1119-23. PubMed ID: 11078796
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Re: tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 study.
    Love RR
    J Natl Cancer Inst; 1999 Nov; 91(21):1891-2. PubMed ID: 10547398
    [No Abstract]   [Full Text] [Related]  

  • 12. Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study.
    Fisher B; Costantino JP; Wickerham DL; Cecchini RS; Cronin WM; Robidoux A; Bevers TB; Kavanah MT; Atkins JN; Margolese RG; Runowicz CD; James JM; Ford LG; Wolmark N
    J Natl Cancer Inst; 2005 Nov; 97(22):1652-62. PubMed ID: 16288118
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The interruption of a study following an "ad interim" analysis. The example of the NSABP-P1 study].
    Savarese A
    Suppl Tumori; 2004; 3(4):S23-4. PubMed ID: 15206204
    [No Abstract]   [Full Text] [Related]  

  • 14. [The ATAC study on adjuvants in breast cancer].
    Bravi S
    Suppl Tumori; 2004; 3(4):S15. PubMed ID: 15206200
    [No Abstract]   [Full Text] [Related]  

  • 15. Endometrial adenosarcoma with adjuvant tamoxifen therapy for primary breast carcinoma.
    Jagavkar RS; Shakespeare TP; Stevens MJ
    Australas Radiol; 1998 May; 42(2):157-8. PubMed ID: 9599835
    [No Abstract]   [Full Text] [Related]  

  • 16. [Tamoxifen and breast cancer: is everything known already?].
    Marchetti P; Porzio G; Trapasso T; Baldi PL; Ficorella C
    Tumori; 1998; 84(6):A1-5. PubMed ID: 10080686
    [No Abstract]   [Full Text] [Related]  

  • 17. Meeting highlights: International consensus panel on the treatment of primary breast cancer.
    Love RR
    J Clin Oncol; 2002 Apr; 20(7):1955-6; author reply 1956-7. PubMed ID: 11919263
    [No Abstract]   [Full Text] [Related]  

  • 18. Tamoxifen: a new risk factor for cerebral sinus thrombosis.
    Masjuan J; Pardo J; Callejo JM; Andrés MT; Alvarez-Cermeño JC
    Neurology; 2004 Jan; 62(2):334-5. PubMed ID: 14745086
    [No Abstract]   [Full Text] [Related]  

  • 19. Tamoxifen therapy--long-term results and complications.
    Moore MP; Kinne DW
    Adv Surg; 1996; 29():263-9. PubMed ID: 8720007
    [No Abstract]   [Full Text] [Related]  

  • 20. Trends in use of adjuvant multi-agent chemotherapy and tamoxifen for breast cancer in the United States: 1975-1999.
    Mariotto A; Feuer EJ; Harlan LC; Wun LM; Johnson KA; Abrams J
    J Natl Cancer Inst; 2002 Nov; 94(21):1626-34. PubMed ID: 12419789
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.